New cystic fibrosis drug candidate begins first human safety tests
NCT ID NCT07437105
First seen Feb 28, 2026 · Last updated Jun 15, 2026 · Updated 15 times
Summary
This early-stage study is testing the safety of a new drug called VX-272 in 128 healthy volunteers. Researchers want to see how the body handles the drug and if it causes any side effects. This is a first step before testing the drug in people with cystic fibrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion - Tempe
RECRUITINGTempe, Arizona, 85283, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.